Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
Here are the five latest drugs or medical devices approved by the FDA since Dec. 13.
La Jolla Pharmaceutical won FDA approval Thursday for Giapreza, a drug that treats dangerously low blood pressure in adults with septic or other distributive shock.
A Type 2 diabetes drug, developed by Merck & Co. and Pfizer, won FDA approval Dec. 19., according to Reuters.
Here are six articles Becker's Hospital Review published in the last week, highlighting the FDA's crackdown on 'high-risk' alternative medicines, Teva Pharmaceuticals' layoff plan, and a first-of-its kind gene therapy to treat an inherited form of blindness, among other topics.
The FDA finalized a rule stating that triclosan and 23 other active ingredients are not "generally recognized as safe and effective for use in over-the-counter healthcare antiseptic products." The OTC products the rule refers to include healthcare personnel hand washes…
The French competition authority fined Johnson & Johnson 25 million euros ($29.62 million) for allegedly stalling generic copies of its pain medication Durogestic from entering the market, according to CNBC.
The FDA approved Luxturna, a first-of-its-kind gene therapy, to treat a rare form of inherited vision loss that can result in complete blindness.
Pfizer's board of directors approved a $10 billion share repurchase program Monday and raised its quarterly dividend, according to CNBC.
The Food and Drug Administration on Monday issued a draft proposal of a new, risk-based enforcement policy to strengthen regulations on homeopathic therapies deemed most likely to pose health threats to consumers.
The FDA proposed a new regulation approach Monday to crack down on the growing number of homeopathic remedies that show no clinical benefit.